Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses
Resmetirom (Rezdiffra TM ), a liver-directed thyroid hormone receptor- (THR-) agonist, received accelerated FDA approval in March 2024 as the first agent specifically indicated for non-cirrhotic MASH with moderate-to-advanced fibrosis (F2-F3), based on the MAESTRO-NASH trial demonstrating MASH resolution and fibrosis improvement
Burillo J, Marques P, Jimenez B, Gonzalez-Blanco C, Benito M, Guillen C
Laboratory and animal studies suggest GLP-1 receptor agonists may also inhibit nuclear factor-kappa B (NF-B) signaling, a key pathway in inflammatory gene expression, and reduce oxidative stress through enhanced antioxidant enzyme activity
Magnesium glycinate (200 to 400mg before bed)
Common side effects may include: Most side effects are mild and temporary